Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Apr 5, 2022
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is examining a treatment called transcranial direct current stimulation (tDCS) for people with Huntington's Disease (HD). The main goal is to see how safe and acceptable this treatment is, as well as how well it helps with behavioral and cognitive symptoms, like mood changes and memory issues, in patients who are in the early to middle stages of HD. The trial is currently looking for participants aged 18-85 who have a confirmed HD diagnosis and are experiencing mild to moderate behavioral symptoms, such as anxiety or depression. Participants must have stable medication for at least a month and cannot have certain medical conditions, like epilepsy or severe cognitive disorders.
If you or someone you know is eligible and decides to participate, you can expect to receive tDCS treatment at home, which involves using a gentle electrical current to stimulate the brain. Caregivers are also invited to be part of the study, as long as they can assist the participant without their own serious health issues. This trial aims to better understand how tDCS can help improve the quality of life for those living with Huntington's Disease.
Gender
ALL
Eligibility criteria
- Participant:
- Inclusion Criteria:
- • confirmed HD mutation carriers
- • early (stages 1 and 2) or moderate (stage 3) stages according to Shoulson-Fahn
- • exhibit mild to moderate behavioral symptoms, such as clinically diagnosed apathy, irritability, anxiety, depression, aggression and repetition
- • stable doses of medications for at least one month
- Exclusion Criteria:
- • unstable medical conditions
- • history of epilepsy
- • metallic objects in the brain
- • clinical diagnosis of major cognitive disorder or dementia
- • Have risk of suicidal behavior, defined as any suicidal behavior or suicidal ideation of type 4
- Caregiver:
- Inclusion Criteria:
- • -willingness to participate in the study
- Exclusion Criteria:
- • -motor/cognitive symptoms related to Alzheimer's disease or Huntington's disease that might impair the ability to assist the participant during the research study.
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Erin Stimming, MD
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials